Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Julphar
Harvard Business School
AstraZeneca
Moodys
Chubb
Dow
Fuji
Argus Health

Generated: December 12, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AMINOLEVULINIC ACID HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Aminolevulinic Acid Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00002963 Photodynamic Therapy in Treating Patients With Skin Cancer Completed Roswell Park Cancer Institute Phase 2 RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photodynamic therapy using aminolevulinic acid cream may be effective in treating patients with skin cancer. PURPOSE: This randomized phase II trial is studying how well photodynamic therapy works in treating patients with skin cancer.
NCT00002975 Photodynamic Therapy in Treating Patients With Skin Cancer Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photodynamic therapy using aminolevulinic acid may be effective in treating patients with skin cancer. PURPOSE: This randomized phase II trial is studying how well photodynamic therapy that includes aminolevulinic acid works in treating patients with skin cancer.
NCT00002975 Photodynamic Therapy in Treating Patients With Skin Cancer Completed Roswell Park Cancer Institute Phase 2 RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photodynamic therapy using aminolevulinic acid may be effective in treating patients with skin cancer. PURPOSE: This randomized phase II trial is studying how well photodynamic therapy that includes aminolevulinic acid works in treating patients with skin cancer.
NCT00054171 Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill cancer cells. Photosensitizing drugs such as aminolevulinic acid are absorbed by cancer cells and, when exposed to light, become active and kill the cancer cells. PURPOSE: Randomized phase II trial to study the effectiveness of photodynamic therapy using aminolevulinic acid in treating patients who have cutaneous T-cell lymphoma, B-cell lymphoma, or early chronic lymphocytic leukemia involving the skin.
NCT00054171 Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia Completed Roswell Park Cancer Institute Phase 2 RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill cancer cells. Photosensitizing drugs such as aminolevulinic acid are absorbed by cancer cells and, when exposed to light, become active and kill the cancer cells. PURPOSE: Randomized phase II trial to study the effectiveness of photodynamic therapy using aminolevulinic acid in treating patients who have cutaneous T-cell lymphoma, B-cell lymphoma, or early chronic lymphocytic leukemia involving the skin.
NCT00241670 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid Completed medac GmbH Phase 3 The aim of the study "Fluorescence-guided resection of malignant gliomas with 5-Aminolevulinic acid (5-ALA) vs. conventional resection" is to determine how accurately contrast agent-accumulating tumour can be removed by primary surgery and to assess the clinical usefulness of this method.
NCT00467610 Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS Terminated H. Lundbeck A/S Phase 2 This is a Phase II, open-label clinical trial examining the role of Panhematin® in patients with MDS. The objective of this study is to evaluate the safety and efficacy of Panhematin® (hematin for injection) in the treatment of adult patients (≥ 18 years of age) with low-risk MDS. The study will be conducted on an outpatient basis and will consist of the following: - A Screening Period (within 28 days of the Day 1) - Screening bone marrow aspiration and biopsy up to 60 days prior to receiving study medication - An 8-week Treatment Period (Days 1 through 4 of Week 1, and weekly visits during Weeks 2 through 8); partial and complete responders in any of the three cell lines may continue treatment for an additional 4 weeks - A 6-month Post treatment Follow-up Period (monthly clinic visits during Weeks 12 40)
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Aminolevulinic Acid Hydrochloride

Condition Name

Condition Name for Aminolevulinic Acid Hydrochloride
Intervention Trials
Actinic Keratosis 10
ACTINIC KERATOSES 6
Glioblastoma 5
Glioma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Aminolevulinic Acid Hydrochloride
Intervention Trials
Keratosis, Actinic 21
Keratosis 21
Glioma 10
Glioblastoma 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Aminolevulinic Acid Hydrochloride

Trials by Country

Trials by Country for Aminolevulinic Acid Hydrochloride
Location Trials
United States 82
Finland 4
Japan 2
Netherlands 2
France 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Aminolevulinic Acid Hydrochloride
Location Trials
California 12
New York 8
Illinois 7
Ohio 4
Texas 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Aminolevulinic Acid Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Aminolevulinic Acid Hydrochloride
Clinical Trial Phase Trials
Phase 4 9
Phase 3 8
Phase 2 22
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Aminolevulinic Acid Hydrochloride
Clinical Trial Phase Trials
Completed 23
Recruiting 14
Terminated 8
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Aminolevulinic Acid Hydrochloride

Sponsor Name

Sponsor Name for Aminolevulinic Acid Hydrochloride
Sponsor Trials
DUSA Pharmaceuticals, Inc. 12
National Cancer Institute (NCI) 12
Joint Authority for Päijät-Häme Social and Health Care 4
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Aminolevulinic Acid Hydrochloride
Sponsor Trials
Other 78
Industry 18
NIH 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
UBS
McKesson
Covington
Deloitte
Queensland Health
Cerilliant
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.